These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37653796)

  • 21. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
    Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation.
    Sychev DA; Rozhkov AV; Kazakov RE; Ananichuk AV
    Drug Metab Pers Ther; 2016 Sep; 31(3):173-8. PubMed ID: 27662649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: influence on quality of long-term anticoagulation.
    Nahar R; Saxena R; Deb R; Parakh R; Shad S; Sethi PK; Takkar P; Verma IC
    Pharmacol Rep; 2014 Apr; 66(2):243-9. PubMed ID: 24911077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes.
    Teichert M; Eijgelsheim M; Uitterlinden AG; Buhre PN; Hofman A; De Smet PA; Visser LE; Stricker BH
    Pharmacogenet Genomics; 2011 Jan; 21(1):26-34. PubMed ID: 21063236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genotype polymorphisms of GGCX, NQO1, and VKORC1 genes associated with risk susceptibility in patients with large-artery atherosclerotic stroke.
    Shyu HY; Fong CS; Fu YP; Shieh JC; Yin JH; Chang CY; Wang HW; Cheng CW
    Clin Chim Acta; 2010 Jun; 411(11-12):840-5. PubMed ID: 20193673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Impact of six genetic polymorphisms on Warfarin maintenance dose variation in Chinese Han population].
    Lou Y; Han L; Li Y; Zhang X; Liu Z; Tang M; Yu H; Wang W; Xu J; Liu H; Li Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Jun; 31(3):367-71. PubMed ID: 24928022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey.
    Kocael A; Eronat AP; Tüzüner MB; Ekmekçi A; Orhan AL; İkizceli İ; Yılmaz-Aydoğan H; Öztürk O
    Mol Biol Rep; 2019 Apr; 46(2):1825-1833. PubMed ID: 30712247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses.
    Di Fusco D; Ciccacci C; Rufini S; Forte V; Novelli G; Borgiani P
    Thromb Res; 2013 Jul; 132(1):123-6. PubMed ID: 23726967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytochrome P450 family 4 subfamily F member 2 (CYP4F2) rs1558139, rs2108622 polymorphisms and susceptibility to several cardiovascular and cerebrovascular diseases.
    Zhang T; Yu K; Li X
    BMC Cardiovasc Disord; 2018 Feb; 18(1):29. PubMed ID: 29426278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.
    Suriapranata IM; Tjong WY; Wang T; Utama A; Raharjo SB; Yuniadi Y; Tai SS
    BMC Med Genet; 2011 Jun; 12():80. PubMed ID: 21639946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
    Takeuchi F; McGinnis R; Bourgeois S; Barnes C; Eriksson N; Soranzo N; Whittaker P; Ranganath V; Kumanduri V; McLaren W; Holm L; Lindh J; Rane A; Wadelius M; Deloukas P
    PLoS Genet; 2009 Mar; 5(3):e1000433. PubMed ID: 19300499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese.
    Cha PC; Mushiroda T; Takahashi A; Kubo M; Minami S; Kamatani N; Nakamura Y
    Hum Mol Genet; 2010 Dec; 19(23):4735-44. PubMed ID: 20833655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk.
    Ivashchenko D; Rusin I; Sychev D; Grachev A
    Medicina (Kaunas); 2013; 49(12):517-21. PubMed ID: 24858991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.
    Cerezo-Manchado JJ; Roldan V; Rosafalco M; Anton AI; Arroyo AB; Garcia-Barbera N; Martínez AB; Padilla J; Corral J; Vicente V; Gonzalez-Conejero R
    Pharmacogenomics; 2014 May; 15(7):987-96. PubMed ID: 24956252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dietary and genetic influences on hemostasis in a Yup'ik Alaska Native population.
    Au NT; Reyes M; Boyer BB; Hopkins SE; Black J; O'Brien D; Fohner AE; Yracheta J; Thornton T; Austin MA; Burke W; Thummel KE; Rettie AE
    PLoS One; 2017; 12(4):e0173616. PubMed ID: 28376131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of genetic and clinical factors on warfarin therapy in patients early after heart valve replacement surgery.
    Li B; Liu R; Wang C; Ren C; Zhang S; Zhang F; Zhang J; Liu S; Wei Y; Liu W; Song B; Wu X
    Eur J Clin Pharmacol; 2019 Dec; 75(12):1685-1693. PubMed ID: 31444512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy.
    Hirai K; Yamada Y; Hayashi H; Tanaka M; Izumiya K; Suzuki M; Yoshizawa M; Moriwaki H; Akimoto T; Tsuji D; Inoue K; Itoh K
    Thromb Res; 2015 May; 135(5):861-6. PubMed ID: 25747538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.
    Ma C; Zhang Y; Xu Q; Yang J; Zhang Y; Gao L; Xu B; Wang H; Li Y; Lu C; Yin T
    Int J Hematol; 2012 Dec; 96(6):719-28. PubMed ID: 23104259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of
    Li W; Zhao P; Chen L; Lai X; Shi G; Li L; Dong J
    Pharmacogenomics; 2020 Jan; 21(2):101-110. PubMed ID: 31854268
    [No Abstract]   [Full Text] [Related]  

  • 40. Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.
    Ajmi M; Omezzine A; Achour S; Amor D; Hamdouni H; Ismaïl FBF; Rejeb NB; Kechrid CL; Boughzela E; Bouslama A
    Eur J Clin Pharmacol; 2018 Jun; 74(6):711-722. PubMed ID: 29479633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.